Stocks ended a strong two-week run with a thud Friday as financial stocks took a beating and weakness seeped into other sectors.
The Dow slid on Friday after the Federal Reserve's plan to rekindle consumer and small business lending fell short of expectations...
Stocks were mixed Friday after a strong two-week run as financial stocks continued to struggle as some investors locked in profits. Still, Wall Street could close with its first string of consecutive positive weeks in nearly a year.
The Dow fell on Thursday largely due to concerns that the Federal Reserve's latest efforts to battle the recession are too costly and untested...
US Markets recorded their best week since November, riding four consecutive days of gains, making traders question whether we have found the bottom or if this is merely a bear bounce.
Shares of Dow component Merck rare getting a nice little shot in the arm this morning on an upgrade by Dr. Tim Anderson at Sanford C. Bernstein. He's putting an "Outperform" or "Buy" rating on MRK and raising his target price three bucks to $30.
Anyone out there who sees hope in the stock market must be on drugs. And I am: Lipitor and Novasc from Pfizer, Vasotec from Merck, and four other pills, all of which I gobble every day to stop myself from blowing a gasket. So let me say, with some personal pill-popping experience, that this may be a great time to buy drug stocks.
Even better: Events that could push the Dow up another 1,000 points.
Stocks bounced back after a rocky start Thursday as oil prices rebounded and investors were cheered by a better-than-expected retail-sales.
They may have the same name, but America's oldest teenager Dick Clark and Merck's Chairman and CEO Dick Clark appear to have little else in common. One loves the camera, the other not so much.
With cash scarce, credit tight and big drug companies intent on branching into biotechnology themselves, struggling bio-tech start-ups may no longer get second and third chances to succeed from thier investors, the New York Times reports.
The Dow fell modestly in choppy trade after comments from billionaire investor Warren Buffett dragged down sentiment on Monday.
Could Merck’s acquisition of Schering-Plough trigger a slew of M&A deals?
Stocks retreated in a yo-yo session as an earlier advance in the shares of energy and big-cap technology companies dissipated. But banks held gains as investors hoped for more clarity on the government plan to firm up the financial system, with Fed Chairman Ben Beranke meeting with President Obama today.
Raising taxes despite a recession? Changing the mortgage deduction during a housing crisis? Cramer finds fault with the White House's plans.
Traders were more excited about GE stabilizing and U.S. banks not dropping on a day when European banks are down, than about the Schering deal.
This is part one of the preliminary transcript and video clips of Warren Buffett's appearances on CNBC's Squawk Box on Monday, March 9, 2009.
Stock index futures pointed to a lower open for Wall Street, but were off the day's lows as Dow component Merck announced it will merge with Schering-Plough in a cash and stock deal.
The president’s budget changes sent stocks tumbling, some undeservedly so.
Robert Lloyd of the AIM Summit Fund is not banking on a quick recovery in the economy. So what's his investment strategy?